The Menarini Group, an Italy-based pharmaceutical and diagnostics company, announced on Thursday that it has received marketing authorisation from the European Commission for ELZONRIS (tagraxofusp) as monotherapy intended for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
This approval follows the positive opinion received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on the outcome of the clinical trial conducted in patients with treatment-naïve or previously-treated BPDCN.
The product has received orphan designation in Europe, and is now the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy in Europe to address this high unmet medical need.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT